Drugs / BMN 351
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06280209 | Jan 2024 → Apr 2027 expected | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07573631 | Apr 2026 → Dec 2031 expected | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280209 ↗ |
| Modality | Antisense oligonucleotide | “Anti-sense Oligonucleotide BMN 351 will be administered intravenously.” NCT06280209 ↗ |
| Route | Intravenous | “administered intravenously” NCT06280209 ↗ |